Colorectal Cancer
Colon Cancer, Colorectal Cancer, Bowel Cancer, HIPEC
Colorectal Cancer Treatment Specialists
American Society of Colon and Rectal Surgeons
American Society of Colon & Rectal Surgeons (ASCRS)
www.fascrs.org
www.fascrs.org
Gender Differences in Colon Cancer Treatment
Gender Differences in Colon Cancer Treatment.
Oliver JS, Martin MY, Richardson L, Kim Y, Pisu M.
Source
1 Capstone College of Nursing, University of Alabama , Tuscaloosa, Alabama.
Abstract Background:
Despite women suffering a disproportionate burden of colon cancer mortality, few studies have examined gender differences in evidence-based treatment, especially in poorer states like Alabama.
Objective: To describe colon cancer treatment in older patients diagnosed in Alabama by gender.
Methods: Colon cancer patients 65 years and older diagnosed in 2000-2002 were identified from the Alabama Statewide Cancer Registry (N=1785).
Treatment was identified from Medicare claims for 1999-2003. Outcomes were (1) receipt of surgery and adjuvant 5-fluorouracil chemotherapy (5FU) and (2) 5FU treatment duration (0-4, 5-7, and >7 months).
Generalized Estimating Equation (GEE) models were used to determine significant gender differences, adjusting for clustering at the reporting hospital level, and controlling for race, age, stage, comorbid conditions, census tract-level socioeconomic variables, and adverse chemotherapy effects (when analyzing 5FU duration).
Results: Overall, 93.9% of the patients received surgery.
Of stage II-III patients undergoing surgery, 60.4% stage III and 25.6% stage II patients received 5FU.
Compared with men, women were more likely to have surgery (95.5% vs. 92.2%, p=0.003), less likely to have 5FU (38.6% vs. 45.2%, p=0.02), and more likely to have 0-4 months of 5FU (32.9% vs. 24.9%, p=0.05).
Gender differences were significant for having chemotherapy (adjusted odds ratio [aOR] 0.78, confidence interval [CI] 0.61-1.00, p=0.049), but not for having 0-4 months of 5FU when adjusting for adverse effects (aOR 1.36, CI 0.95-1.94, p=0.09).
Conclusions: In Alabama, some gender differences in stage-specific colon cancer treatment are worth further scrutiny.
J Womens Health (Larchmt). 2013 Mar 26. [Epub ahead of print]
PMID: 23531098 [PubMed - as supplied by publisher]
Colorectal Cancer Prevention
The Centers for Disease Control says:
At least 6 out of every 10 deaths from colorectal cancer could be prevented if all men and women aged 50 years or older were screened routinely.
Learn about prevention and screening
Source: CDC
At least 6 out of every 10 deaths from colorectal cancer could be prevented if all men and women aged 50 years or older were screened routinely.
Learn about prevention and screening
Source: CDC
Colorectal Cancer Detection
Colon Cancer Screening
Free Colorectal Cancer Screening in 25 States and 4 Tribes
Colorectal Cancer Facts
Colorectal Cancer Basic Information
Cancer Care Conferences
What is Colon Cancer?
Resources for Colon Cancer Patients and Their Families
Senior Colon Cancer Patients Require Specialized Post Op Care
Importance of the First Postoperative Year in the Prognosis of Elderly Colorectal Cancer Patients
Source: Annals of Surgery, March 2011
Seniors with Colorectal Cancer
Colorectal Cancer Prevention
Colorectal Cancer Risk Factors
Colorectal Cancer Fact Sheet: Causes and Risks for Colorectal Cancer
Source: National Cancer Institute
Colon Cancer Causes and Risks
Source: Pub Med
Colorectal Cancer Risk Factors
Source: CDC
Source: National Cancer Institute
Colon Cancer Causes and Risks
Source: Pub Med
Colorectal Cancer Risk Factors
Source: CDC
Nutrition for Colon Cancer Patients
Exercise to Prevent Colon Cancer!
Colorectal Cancer en Espanol
Colorectal Cancer en Espanol
Source: CDC 03.07.12
Síntomas del cáncer colorrectal
¿Debe hacerse las pruebas de detección del #cáncer de colon
aunque no tenga ningún síntoma?
Informacion de Cancer Colorrectal en Espanol
Advanced Colon and Rectal Cancer
Garrett M. Nash, MD, MPH
Assistant Attending Surgeon
Colorectal Service
Memorial Sloan-Kettering Cancer Center
Assistant Professor of Surgery
Weill-Cornell Medical College New York, NY
Colorectal cancer (CRC) affects approximately 150,000 people each year in the United States and more than one third of those will have metastatic disease at some point in their disease.
Prior to 2000, the only effective chemotherapy for metastatic CRC was 5-fluorourcil (5-FU). New agents have been developed and successfully studied in randomized trials in the adjuvant and palliative settings: capcitebine, oxaliplatin, irinotecan, bevacizumab, and cetuximab. The combination of infusional 5-FU with leucovorin and oxaliplatin (FOLFOX) is now accepted as standard of care for first line therapy in the adjuvant(1) and metastatic setting.
Read entire article…
Assistant Attending Surgeon
Colorectal Service
Memorial Sloan-Kettering Cancer Center
Assistant Professor of Surgery
Weill-Cornell Medical College New York, NY
Colorectal cancer (CRC) affects approximately 150,000 people each year in the United States and more than one third of those will have metastatic disease at some point in their disease.
Prior to 2000, the only effective chemotherapy for metastatic CRC was 5-fluorourcil (5-FU). New agents have been developed and successfully studied in randomized trials in the adjuvant and palliative settings: capcitebine, oxaliplatin, irinotecan, bevacizumab, and cetuximab. The combination of infusional 5-FU with leucovorin and oxaliplatin (FOLFOX) is now accepted as standard of care for first line therapy in the adjuvant(1) and metastatic setting.
Read entire article…
Colorectal Cancer: Phase II Study at NCI NIH
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux®) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
NCI-06-C-0164, NCT00326495
For information contact:
Shivaani Kummar, M.D., F.A.C.P.
Principal Investigator
Phone: 301-435-0517
Fax: 301-496-0826
kummars@mail.nih.gov
NCI-06-C-0164, NCT00326495
For information contact:
Shivaani Kummar, M.D., F.A.C.P.
Principal Investigator
Phone: 301-435-0517
Fax: 301-496-0826
kummars@mail.nih.gov
Colorectal Cancer Screening Report
Colorectal Cancer Screening Report: Incidence, and Mortality in the United States, 2002--2010
Source: Centers for Disease Control 07.05.11
Colorectal Cancer Awareness
Ostomy Care for Colon Cancer Patients
Ken leads an active life with an ostomy!
Recommended Reading: The ABC of Colorectal Cancer
Do Obese White Women Avoid Colon Cancer Screening?
Obese White Women Less Likely to Seek Colon Cancer Screening
Source: Johns Hopkins University 4.04.12
Source: Johns Hopkins University 4.04.12
Genetic Aberrations in Relation to Colon Cancer
Genetic Aberrations Seen as a Path to Stop Colon Cancer
Source: NYT 08.01.12 by Gina Kolata
More than 200 researchers, including Dr Garrett M Nash of Memorial Sloan Kettering, investigated colon cancer tumors genetic vulnerabilities that could lead to powerful new treatments. The hope is that drugs designed to strike these weak spots will eventually stop a cancer is now almost inevitably fatal once it has spread. Read article>>>
Source: NYT 08.01.12 by Gina Kolata
More than 200 researchers, including Dr Garrett M Nash of Memorial Sloan Kettering, investigated colon cancer tumors genetic vulnerabilities that could lead to powerful new treatments. The hope is that drugs designed to strike these weak spots will eventually stop a cancer is now almost inevitably fatal once it has spread. Read article>>>
Role of Mutations in Colon Cancer Development
Researchers at Fred Hutchinson Cancer Research Center studied the role of mutations in colon cancer development.
Source:Medical News Today 06.10.12
Open vs Laparoscopic Resection for Stage IV Colorectal Cancer
Open Versus Laparoscopic Resection of Primary Tumor for Incurable Stage IV Colorectal Cancer: A Large Multicenter Consecutive Patients Cohort Study
Hida, Koya MD, PhD; Hasegawa, Suguru MD, PhD; Kinjo, Yousuke MD; Yoshimura, Kenichi PhD; Inomata, Masafumi MD, PhD; Ito, Masaaki MD, PhD; Fukunaga, Yosuke MD, PhD; Kanazawa, Akiyoshi MD, PhD; Idani, Hitoshi MD, FACS, PhD; Sakai, Yoshiharu MD, FACS, PhD; Watanabe, MD, FACS, PhD; Japan Society of Laparoscopic Colorectal Surgery
Source: Annals of Surgery POST AUTHOR CORRECTIONS, 24 February 2012
Objective: To investigate the hypothesis that laparoscopic primary tumor resection is safe and effective when compared with the open approach for colorectal cancer patients with incurable metastases.
Background: There are only a few reports with small numbers of patients on laparoscopic tumor resection for stage IV colorectal cancer.
Methods: Data from consecutive patients who underwent palliative primary tumor resection for stage IV colorectal cancer between January 2006 and December 2007 were collected retrospectively from 41 institutions. Short- and long-term outcomes were compared between patients who underwent laparoscopic or open resection.
Results: A total of 904 patients (laparoscopic group: 226, open group: 678) with a median age of 64 years (range: 22-95) were included in the analysis. Conversion was required in 28 patients (12.4%) and the most common reasons for conversion (23/28: 82%) were bulky or invasive tumors. There was no 30-day postoperative mortality in either group. The complication rate (NCI-CTCAE grade 2-4) after laparoscopic surgery (17%) was significantly lower than that after open surgery (24%) (P = 0.02), and the difference was greater (4% vs 12%; P < 0.001) when we limited the analysis to severe (>=grade 3) complications. The median length of postoperative hospital stay in the laparoscopic group was significantly shorter than that in the open group (14 vs 17 days; P = 0.002). In univariate analysis, overall survival for the laparoscopic group was significantly better than that for open surgery (median survival time: 25.9 vs 22.3 months, P = 0.04), although no difference was apparent in multivariate analysis.
Conclusions: Compared with open surgery, laparoscopic primary tumor resection has advantages in the short term and no disadvantages in the long term. It is a reasonable treatment option for certain stage IV colorectal cancer patients with incurable disease.
(C) 2012 Lippincott Williams & Wilkins, Inc.
Colon Polyps
"I Have Colon Polyps, Now What?" video presented by MD Anderson
Definition of Colon Cancer from NCI
"Cancer that forms in the tissues of the colon (the longest part of the large intestine). Most colon cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids).Estimated new cases and deaths from colon and rectal cancer in the United States in 2011:
New cases: 101,340 (colon); 39,870 (rectal)
Deaths: 49,380 (colon and rectal combined)"
"Cancer that forms in the tissues of the colon (the longest part of the large intestine). Most colon cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids).Estimated new cases and deaths from colon and rectal cancer in the United States in 2011:
New cases: 101,340 (colon); 39,870 (rectal)
Deaths: 49,380 (colon and rectal combined)"
Colon Cancer Screening
Overview of Colon Cancer Screening at MD Anderson
Colorectal Cancer Screening
Colorectal Cancer and Chemotherapy
Colorectal Cancer Screening Options
Source: NYU
Colorectal Cancer Exercise and Dietary Guidelines Film
Source: NYU
Colon Cancer and Gene Variations
Gene Variations and Bowel Cancer Survival
Source: NCRI, Cardiff Wales, 2010
Source: NCRI, Cardiff Wales, 2010
Chemotherapy for Colorectal Cancers
Colorectal Cancer Treatment Highlights
Highlights from ASCO 2011
Source: Fight Colorectal Cancer
Source: Fight Colorectal Cancer
HIPEC is Effective for the Treatment of Colorectal Cancer
Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma
by Tristan D. Yan, Deborah Black, Renaldo Savady, Paul H. Sugarbaker
Sources: Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington, DC; and the School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia.Address reprint requests to Paul H. Sugarbaker, MD, 106 Irving St, NW, Suite 3900N, Washington, DC, 20010; e-mail: Paul.Sugarbaker@medstar.net
by Tristan D. Yan, Deborah Black, Renaldo Savady, Paul H. Sugarbaker
Sources: Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington, DC; and the School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia.Address reprint requests to Paul H. Sugarbaker, MD, 106 Irving St, NW, Suite 3900N, Washington, DC, 20010; e-mail: Paul.Sugarbaker@medstar.net
Is HIPEC Effective for the Treatment of Colorectal Cancer?
Cytoreductive Surgery and Hyperthermic Intraperitonal Chemotherapy: History Repeating Itself or a New Standard?
By David P. Ryan, MD
Harvard Medical School, Boston, MA and Massachusetts General Hospital Cancer Center, Boston, MA.
Source: © 2011 by American Society of Clinical Oncology. 1092-9118/10/1-10
By David P. Ryan, MD
Harvard Medical School, Boston, MA and Massachusetts General Hospital Cancer Center, Boston, MA.
Source: © 2011 by American Society of Clinical Oncology. 1092-9118/10/1-10
Hereditary or Familial Cancers
Hereditary Cancers including gastric and colon cancers
Source: Creighton University
Hereditary Cancer Genes
Source: Creighton University
Hereditary Cancers including colorectal cancers
Source: MD Anderson
Source: Creighton University
Hereditary Cancer Genes
Source: Creighton University
Hereditary Cancers including colorectal cancers
Source: MD Anderson
Recommended Reading
Colon and Rectal Cancer: A Comprehensive Guide for Patients and Families
Author: Lorraine Johnston
This book is a helpful addition to the library of any colorectal or gastrointestinal cancer patient.
Among the practical topics addressed are:
Managing your Finances, Insurance, and Employment During Medical Treatment
Tips for Communicating with Medical Personnel
Sexuality and Intimacy
Stress and the Immune System
Traveling Long Distance for Medical Care
Staging System Equivalents and, much more!
Educate yourself, and your loved ones with this informative book!
Author: Lorraine Johnston
This book is a helpful addition to the library of any colorectal or gastrointestinal cancer patient.
Among the practical topics addressed are:
Managing your Finances, Insurance, and Employment During Medical Treatment
Tips for Communicating with Medical Personnel
Sexuality and Intimacy
Stress and the Immune System
Traveling Long Distance for Medical Care
Staging System Equivalents and, much more!
Educate yourself, and your loved ones with this informative book!
Lynch Syndrome: Inherited Cancer
Lynch Syndrome is the most common form of inherited colorectal cancer; summary of a public health meeting: Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting.
Source:
Bellcross CA, Bedrosian SR, Daniels E, Duquette D, Hampel H, Jasperson K, Joseph DA, Kaye C, Lubin I, Meyer LJ, Reyes M, Scheuner MT, Schully SD, Senter L, Stewart SL, St Pierre J, Westman J, Wise P, Yang VW, Khoury MJ.
Source
1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
January 2012
Abstract:
"Lynch syndrome is the most common cause of inherited colorectal cancer, accounting for approximately 3% of all colorectal cancer cases in the United States."
In 2009, an evidence-based review process conducted by the independent Evaluation of Genomic Applications in Practice and Prevention Working Group resulted in a recommendation to offer genetic testing for Lynch syndrome to all individuals with newly diagnosed colorectal cancer, with the intent of reducing morbidity and mortality in family members.
To explore issues surrounding implementation of this recommendation, the Centers for Disease Control and Prevention convened a multidisciplinary working group meeting in September 2010.
This article reviews background information regarding screening for Lynch syndrome and summarizes existing clinical paradigms, potential implementation strategies, and conclusions which emerged from the meeting. It was recognized that widespread implementation will present substantial challenges, and additional data from pilot studies will be needed. However, evidence of feasibility and population health benefits and the advantages of considering a public health approach were acknowledged.
Lynch syndrome can potentially serve as a model to facilitate the development and implementation of population-level programs for evidence-based genomic medicine applications involving follow-up testing of at-risk relatives. Such endeavors will require multilevel and multidisciplinary approaches building on collaborative public health and clinical partnerships.Genet Med 2012:14(1):152-162.
Source:
Bellcross CA, Bedrosian SR, Daniels E, Duquette D, Hampel H, Jasperson K, Joseph DA, Kaye C, Lubin I, Meyer LJ, Reyes M, Scheuner MT, Schully SD, Senter L, Stewart SL, St Pierre J, Westman J, Wise P, Yang VW, Khoury MJ.
Source
1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
January 2012
Abstract:
"Lynch syndrome is the most common cause of inherited colorectal cancer, accounting for approximately 3% of all colorectal cancer cases in the United States."
In 2009, an evidence-based review process conducted by the independent Evaluation of Genomic Applications in Practice and Prevention Working Group resulted in a recommendation to offer genetic testing for Lynch syndrome to all individuals with newly diagnosed colorectal cancer, with the intent of reducing morbidity and mortality in family members.
To explore issues surrounding implementation of this recommendation, the Centers for Disease Control and Prevention convened a multidisciplinary working group meeting in September 2010.
This article reviews background information regarding screening for Lynch syndrome and summarizes existing clinical paradigms, potential implementation strategies, and conclusions which emerged from the meeting. It was recognized that widespread implementation will present substantial challenges, and additional data from pilot studies will be needed. However, evidence of feasibility and population health benefits and the advantages of considering a public health approach were acknowledged.
Lynch syndrome can potentially serve as a model to facilitate the development and implementation of population-level programs for evidence-based genomic medicine applications involving follow-up testing of at-risk relatives. Such endeavors will require multilevel and multidisciplinary approaches building on collaborative public health and clinical partnerships.Genet Med 2012:14(1):152-162.
Colorectal cancer surgery in the elderly: acceptable morbidity?
Ong ES, Alassas M, Dunn KB, Rajput A.
Abstract
BACKGROUND: Because of the increase in the geriatric population, an increasing number of elderly patients are being treated for colorectal cancer. The purpose of this study was to evaluate perioperative morbidity and mortality in this population.
METHODS: A retrospective chart review was performed for patients 80 years of age or older who underwent surgery for colorectal cancer (1993-2006).
RESULTS: Ninety patients were identified, with a median age of 84 years. More than 90% presented with symptoms; the remaining were diagnosed by screening colonoscopy. Emergent surgery was required in 10%. The morbidity rate was 21% and the overall 30-day mortality rate was 1.1%. Morbidity was higher in patients who required surgery emergently.
CONCLUSIONS: Despite advanced age, the majority of patients in this study did well. Postoperative morbidity was higher than in the general population, but we believe it was acceptably low in most patients. Colorectal surgery appears to be safe in most elderly patients.
Am J Surg. 2008 Mar;195(3):344-8
BACKGROUND: Because of the increase in the geriatric population, an increasing number of elderly patients are being treated for colorectal cancer. The purpose of this study was to evaluate perioperative morbidity and mortality in this population.
METHODS: A retrospective chart review was performed for patients 80 years of age or older who underwent surgery for colorectal cancer (1993-2006).
RESULTS: Ninety patients were identified, with a median age of 84 years. More than 90% presented with symptoms; the remaining were diagnosed by screening colonoscopy. Emergent surgery was required in 10%. The morbidity rate was 21% and the overall 30-day mortality rate was 1.1%. Morbidity was higher in patients who required surgery emergently.
CONCLUSIONS: Despite advanced age, the majority of patients in this study did well. Postoperative morbidity was higher than in the general population, but we believe it was acceptably low in most patients. Colorectal surgery appears to be safe in most elderly patients.
Am J Surg. 2008 Mar;195(3):344-8
The PMP Pals' Network supports the conservation of fuel and paper products.
This page is sponsored in memory of Doris Schoby...
...by her devoted husband, David Wolden
Copyright 2013 by the PMP Pals' Network/All rights reserved. Updated 04.17.13